X
All Data
Upgrade this company profile, update & customize all content// Ask PharmaCompass, click HERE
Lead Product(s): EI1071
Therapeutic Area: Neurology Product Name: EI1071
Highest Development Status: Phase I Product Type: Small molecule
Partner/Sponsor/Collaborator: Alzheimer's Association
Deal Size: $1.0 million Upfront Cash: Undisclosed
Deal Type: Funding August 26, 2020
Details:
Grant Program will support a U.S. FDA-approved first-in-human phase 1 clinical trial of its lead drug candidate, EI1071, an orally available, highly potent Colony-Stimulating Factor 1 Receptor (CSF1R) inhibitor.
Active Pharmaceutical Ingredients
Finished Drug Formulations
Prices
Excipients
Services
Marketplace
